source
- FDA imposes partial clinical hold on Biohaven's experimental epilepsy drug BHV-7000FDA announced a partial clinical hold on Biohaven's ion channel program, affecting the epilepsy trial of the experimental drug BHV-7000. The hold was issued after the agency requested additional p…
- BridgeBio Oncology shares tumble 24% as it narrows KRAS program focusBridgeBio Oncology Therapeutics saw its stock drop sharply after announcing a strategic shift. The company said it will scale back its broader pipeline to concentrate resources on its lead KRAS in…